Novartis reported Phase 2 data indicating its recently approved hives drug, Rhapsido, produced higher response rates across three doses in a food allergy study. Company investigators presented topline results that frame Rhapsido as a potential entrant into the broader food-allergy market beyond its current urticaria approval. Novartis will assess dose-response, safety, and next steps including potential Phase 3 planning or regulatory discussions if data hold up in detailed analyses. The readout underscores pharma interest in repurposing or extending approvals for immune-modulating agents into adjacent allergic indications.